307 related articles for article (PubMed ID: 36131190)
1. A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.
Khadka P; Dummer J; Hill PC; Katare R; Das SC
Drug Deliv Transl Res; 2023 May; 13(5):1246-1271. PubMed ID: 36131190
[TBL] [Abstract][Full Text] [Related]
2. Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment.
Khadka P; Dummer J; Hill PC; Das SC
Int J Pharm; 2018 Sep; 548(1):244-254. PubMed ID: 29983396
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats.
Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
Eur J Pharm Biopharm; 2021 May; 162():1-11. PubMed ID: 33639255
[TBL] [Abstract][Full Text] [Related]
4. The quest to deliver high-dose rifampicin: can the inhaled approach help?
Khadka P; Dummer J; Hill PC; Das SC
Expert Opin Drug Deliv; 2024; 21(1):31-44. PubMed ID: 38180078
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model.
Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
Int J Pharm; 2021 Mar; 597():120345. PubMed ID: 33545287
[TBL] [Abstract][Full Text] [Related]
7. A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment.
Khadka P; Hill PC; Zhang B; Katare R; Dummer J; Das SC
Int J Pharm; 2020 Sep; 587():119602. PubMed ID: 32663580
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
10. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
11. Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Gupta A; Pandya SM; Mohammad I; Agrawal AK; Mohan M; Misra A
Crit Rev Ther Drug Carrier Syst; 2013; 30(4):277-91. PubMed ID: 23662603
[TBL] [Abstract][Full Text] [Related]
12. Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs.
Ramachandran S; Prakash P; Mohtar N; Kumar KS; Parumasivam T
Pharm Dev Technol; 2023 Dec; 28(10):978-991. PubMed ID: 37937865
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.
Garcia-Contreras L; Sethuraman V; Kazantseva M; Godfrey V; Hickey AJ
J Antimicrob Chemother; 2006 Nov; 58(5):980-6. PubMed ID: 16971416
[TBL] [Abstract][Full Text] [Related]
14. Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis.
Radtke KK; Svensson EM; van der Laan LE; Hesseling AC; Savic RM; Garcia-Prats AJ
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):161-174. PubMed ID: 35285351
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
16. Inhaled drug therapy for treatment of tuberculosis.
Misra A; Hickey AJ; Rossi C; Borchard G; Terada H; Makino K; Fourie PB; Colombo P
Tuberculosis (Edinb); 2011 Jan; 91(1):71-81. PubMed ID: 20875771
[TBL] [Abstract][Full Text] [Related]
17. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
19. Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy.
Berkenfeld K; McConville JT; Lamprecht A
Expert Opin Drug Deliv; 2020 Mar; 17(3):305-322. PubMed ID: 32017637
[No Abstract] [Full Text] [Related]
20. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis.
Hickey AJ; Misra A; Fourie PB
J Pharm Sci; 2013 Nov; 102(11):3900-7. PubMed ID: 23963705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
